Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC) Editorial Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Clinical Trials as Topic
  • Drug Approval
  • Prostatic Neoplasms, Castration-Resistant
  • Research Design

abstract

  • Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Here, we discuss the potential underlying mechanisms, including the activation of glucocorticoid receptors (GR) in progressive mCRPC and the implications for clinical practice.

publication date

  • January 2018

Research

keywords

  • Editorial

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/s41416-018-0239-y

PubMed ID

  • 30344307